Skip to main content
On June 14, 2018, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for use as medication-assisted treatment for opioid dependence. The branded drug Suboxone is marketed by Indivior, Plc. The generics are made by Mylan Technologies Inc. and Dr. Reddy's Laboratories SA. The FDA approved the generics in multiple strengths. Generic oral tablet buprenorphine-naloxone formulations have been available in the United States since 2013. Indivior was spun out from Reckitt Benckiser in 2014. Suboxone Film generates 80% of Indivior’s annual . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463